Yes, you are seeing a highly coordinated hiring surge on the Definium Therapeutics Careers Page. They currently have over 20 executive and director-level roles open across their Greenhouse Job Board.

For a pre-revenue biopharmaceutical firm, this sudden spike in headcount is a major tell. When you look closely at which departments are hiring, it is clear that Definium is actively building out its first commercial launch and field deployment infrastructure to support the 2027/2028 DT120 rollout.

Building the Commercial Architecture

Instead of just hiring scientists, Definium's largest current hiring focus is on corporate launch readiness and human resources:

Director, Talent Acquisition – Commercial:

This specific role is being hired explicitly to "build and scale the recruiting strategy for Definium's first commercial organization". They are hiring the recruiter who will eventually build their massive nationwide sales force.

Commercial Infrastructure: High-level executive postings include roles like Sr. Director, Commercial Finance Launch & Growth and Sr. Director, Sales Training.

Preparing for the REMS Bottleneck (Market Access)

Because DT120 cannot be taken at home and requires clinic certification, they are aggressively staffing their Market Access and Patient Services teams to coordinate with interventional psychiatric clinics:

• Director, Patient Services Operations: Located in the Raleigh/Durham, NC biotech hub, this executive will build out case management infrastructure and navigate FDA REMS compliance.

• Field Strategy Roles: Open roles like Director of Patient Services Site of Care Strategy and Sr. Director of National Accounts focus entirely on getting healthcare facilities onboarded to administer the drug post-approval.

Deploying the Medical "Ground Troops" (Medical Affairs)

A significant chunk of their current open portfolio belongs to Medical Affairs. They are hiring a network of field-based Medical Science Liaisons (MSLs) across the East Coast, Midwest, and West Coast. MSLs are scientific experts who travel to universities and top-tier psychiatric medical centers to educate key opinion leaders on DT120's clinical trials before commercial marketing legally begins.

Late-Stage & System Validation (Clinical Operations/QA)

To push their upcoming Phase 3 trials (like Ascend for depression and Haven for PTSD), they are filling back-end operational gaps:

• Director, Late-Stage Clinical Development: Tasked with managing expanded access programs and real-world evidence tracking.

• Computer System Validation (CSV): Hiring Sr. CSV Analysts and QA Specialists to ensure their data tracking frameworks are 100% compliant with FDA electronic record standards ahead of the 2027 filing.

The compensation figures listed on platforms like Glassdoor match this heavy expansion tier, with many director and senior clinical roles advertising base salaries spanning from $165,000 up to $299,000+ alongside stock options. It shows they are aggressively using their $1.1B cash buffer to buy top-tier pharmaceutical launch talent.

---------------------------------------------------------------------

The Quarterly Expense Breakdown-

The company’s overhead has climbed significantly year-over-year as they scale up clinical infrastructure and finalize their commercial team. In their last reported quarter, the literal cash-driven operating expenses included:

• Research & Development (R&D): $48.7 million per quarter. This covers their active clinical trials like the Phase 3 Ascend depression study and Phase 2a autism trials.

• General & Administrative (G&A): $26.4 million per quarter. This is the bucket funding the current commercial hiring surge, human resources, and marketing logistics.

(Note: While Definium reported a total GAAP net loss of $159.0 million for the quarter, $86.2 million of that was a non-cash, paper-only accounting charge related to warrant liability revaluations caused by their rising stock price, not literal cash leaving the bank.)

Runway and Capital Health-

Despite spending roughly $75 million every three months, Definium is in an exceptionally stable financial position:

• Cash Reserves: They successfully closed a massive public stock offering in June 2026, raising $757.9 million in net proceeds.

• Total Balance Sheet: They ended the first half of the year with $1.1 billion in cash, cash equivalents, and short-term investments.

• Total Runway: Executive management explicitly stated that this capital cushion gives them a 3.75-year operating runway, guaranteeing their operations and commercial launch are fully funded well into 2030.

Hope this helps everyone get a better idea of how things are gonna work from now on! Keep the faith! 😊

More pieces, financial and performance-related, are falling into place for Alphabet's emerging business of selling artificial intelligence accelerator chips, which could provide a boost to Google stock while creating more competition for Nvidia.

Google's newest TPU, called Ironwood, continues to get good reviews.

SemiAnalysis, a semiconductor research and consulting firm, this month said Google's "TPUv7" Ironwood achieves 50% better performance per dollar than Nvidia's Blackwell Ultra chips on InferenceX. It's an open-source, continuous AI inference benchmarking platform created by SemiAnalysis.

Earlier studies showed Google's AI chips consume less power than Nvidia's Blackwell devices. The Ironwood TPUs target both training of AI models and "inferencing" — processing AI workloads.

Google aims to monetize TPU systems through three business models. One is letting companies rent TPU processing at its own cloud business. Also, Google sells TPU systems directly for deployment in customers' data centers. Third, Google also sells TPUs through the Blackstone cloud computing joint venture.

Upside For Google Stock?

In a Sept. 9 research report, Oppenheimer analyst Jason Helfstein was upbeat on Google's AI chip sales. "We are forecasting $170 billion cumulative incremental TPU sales through 2028, which is not in street estimates," he said. "New estimates suggest 15% to 30% upside to Wall Street Google Cloud Platform revenue and 4% to 18% upside to consolidated EPS in 2027/2028, assuming very conservative TPU margins."

Google reported second-quarter cloud-computing revenue of $24.77 billion, up 82% year over year, driven by artificial intelligence workloads, handily beating estimates of $22.46 billion.

For the first time, Google included third-party sales of AI accelerator chips, called tensor-processing units, in cloud revenue.

In Q2, Google said its cloud computing order backlog jumped to $514 billion, up from $460 billion in Q1. The backlog is converted into realized revenue as new data centers come online and crunch artificial intelligence-related workloads — training AI models and processing AI apps.

In a study published in Proceedings of the National Academy of Sciences, the researchers whittled away at LSD's core multiring structure and synthesized new, simplified versions to probe its functionality. The researchers developed several compounds with reduced hallucinogenic and cardiotoxic effects while identifying one compound that produced antipsychotic-like effects.

"By systematically deconstructing LSD, we have identified simplified cores that are better starting points for medicinal chemistry efforts," said study corresponding author David E. Olson, director of the Institute for Psychedelics and Neurotherapeutics and a professor of chemistry and biochemistry and molecular medicine at UC Davis.

LSD is among the many psychedelic drugs that researchers are investigating because of its ability to spur neuron growth and strengthen connections between neurons. A host of neuropsychiatric and neurodegenerative diseases are characterized by the withering of these connections.

We've known the structure of LSD for a long time, but the complexity of its core has really limited our ability to engineer optimized drugs based on its structure," Olson said. "If you can only modify a couple of spots, you're limited in what you can do."

​

Management expressed confidence in the upcoming Panorama data expected in September. The statistical analysis focuses on 100ug versus placebo, while the 50ug arm is included to influence patient expectations and address potential questions around functional unblinding.

The company has regulatory alignment with the agency around plans to file for both GAD and MDD based on data generated to date. Management does not need to establish whether 50ug is effective.

Stifel noted that strong efficacy, clear durability, two indications on the label and favorable provider economics support the firm’s view of DT120 as a blockbuster opportunity.

Who knows. Maybe this has something to do with the movement today. They really want to keep their employees. It's got to be good.

https://clinicaltrials.gov/study/NCT06741228

ClinicalTrials.gov

An official website of the U.S. Department of Health and Human Services, National Institutes of Health, National Library of Medicine, and National Center for Biotechnology Information.

I don't think he would schedule this interview tomorrow morning if the quarter was about to blow up long and strong right here, team!

Sorry for the paywall- I was able to access the article then they would'nt let me copy and paste.

Billionaire investors such as Peter Thiel and Christian Angermayer are believers in the benefits of using psychedelics derived from magic mushrooms, LSD and even toad venom to treat mental health disorders. Now, Big Pharma is getting in on the act too.

Last week, Eli Lilly, the world’s most valuable pharmaceutical company, agreed to buy Thiel-backed psychedelic drug developer AtaiBeckley for up to $3.8bn. Japan’s Otsuka Pharmaceutical acquired biotech company Transcend Therapeutics, focused on psychedelics for post-traumatic stress disorder, for $700mn last month, while AbbVie bought biotech Gilgamesh Pharmaceuticals’ lead psychedelic asset for up to $1.2bn last year.

What’s changed? For one, clinical results have improved. Last month, Definium reported positive results for its LSD-based tablet for depression in a phase 3 trial — which tests a drug on a relatively large population. Compass Pathways released late-stage trial data for a formulation of magic mushrooms earlier this month, showing its treatment for depression may offer longer-lasting effects than existing options, and the company’s FDA application was granted an accelerated commercialisation.  Regulation is also helping. In April, the Trump administration signed an executive order to speed up research and approval of psychedelic treatments. And commercial success is beginning to look less theoretical. J&J’s Spravato, based on a ketamine compound, made $1.7bn of sales last year, up roughly 60 per cent from the previous year. Analysts’ forecasts for its sales in the early 2030s have risen by a quarter over the past year, according to Visible Alpha consensus. 

How big could psychedelics become? For now, the sector’s main target is patients who don’t respond to current treatment for depression. That’s 4mn people in the US by 2036, reckons Berenberg. Say, for the sake of argument, that 5 per cent of this group were treated with Atai’s psychedelics. At even half the current price of J&J’s Spravato, the therapy could generate roughly $6bn in annual sales for Eli Lilly. That is still a fraction of the $85bn Eli Lilly is expected to make from its weight-loss drugs in the mid-2030s, but it would take its neuroscience therapies from its current 2 per cent of total revenue to roughly a tenth, Lex estimates. Psychedelic medicines are harder to scale than a pill: the constraint isn’t the availability of the drug itself but the trained staff, dedicated treatment rooms and hours of supervision that patients require during and after treatment. Still, such therapies address an important unmet need. Once the drugs of the counterculture, psychedelics are now taking their next big trip into Big Pharma’s cabinet.

July 15 (Reuters) - Eli Lilly is ​in talks to acquire psychedelic drugmaker ‌AtaiBeckley and a deal could be announced as soon as this week, Bloomberg News ​reported on Wednesday, citing people ​familiar with the matter.

AtaiBeckley shares soared 66% ⁠in aftermarket trading, while Lilly ​was flat. AtaiBeckley was up 31% so far ​this year and had a market value of $1.97 billion as of Wednesday's close, according to ​LSEG data.

The potential acquisition of Atai Beckley by Eli Lilly marks a significant move in the healthcare sector, particularly in the burgeoning field of psychedelic medicine. Atai Beckley is known for its innovative approach to mental health treatments, focusing on rapid-acting therapies for conditions such as treatment-resistant depression and social anxiety disorder. The negotiations suggest that Eli Lilly is willing to invest in this promising sector, which could enhance its portfolio and market position.

Probably why we bumped after hours. Now would be a good time to release GAD phase 3 trials.

https://www.reuters.com/business/healthcare-pharmaceuticals/eli-lilly-nears-deal-buy-psychedelic-drugmaker-ataibeckley-bloomberg-news-2026-07-15/

Okay I found the link. The video is attached. Very interesting they do this down in Mexico.

This one is actually about toad poison. Imagine that, but these companies are definitely getting a lot of exposure.

An obscure and extremely powerful psychedelic called 5-MeO-DMT is drawing intense interest from the pharmaceutical industry, where biotech companies are racing to turn it into a commercially available treatment for severe mental health disorders, like depression, anxiety and PTSD.

https://www.wsj.com/video/the-race-to-commercialize-the-worlds-most-powerful-psychedelic/F24E9B22-38D3-4BFC-B80A-3B5F73423E0C

https://archive.fast-edgar.com/20260618/AV22222CG222M2Z2222U22YS4J2SG2229282/

If you look in the lower right hand corner of Box #7 it says.

" Nature of Indirect Beneficial Ownership By MorMa Trust"

I looked up what Morma Trust is and get this..

The MorMa Trust is a wildlife conservation and community development organization based in Botswana. It is dedicated to protecting a remote ecosystem near the Okavango Delta, supporting local culture, and managing wildlife habitats to preserve regional migratory routes. [1]

The MorMa Trust focuses on the following primary initiatives:

• Habitat Conservation: Managing large-scale ecosystems to maintain crucial migratory pathways for wildlife traveling to and from the Okavango Delta.
• Community Development: Integrating wildlife conservation with local community empowerment and cultural preservation.
• Sustainable Tourism: Fostering eco-conscious practices to ensure the region is protected for future generations. [1]

For more details on their ongoing projects or how to support their efforts, you can visit the MorMa Trust website.